Article

Coping and self-efficacy in marijuana treatment: results from the marijuana treatment project.

Department of Behavioral Sciences and Community Health, University of Connecticut Health Center, Farmington, 06030, USA.
Journal of Consulting and Clinical Psychology (Impact Factor: 4.85). 01/2006; 73(6):1015-25. DOI: 10.1037/0022-006X.73.6.1015
Source: PubMed

ABSTRACT This study examined whether a coping-skills-based treatment for marijuana dependence operated by encouraging the use of coping skills or via other mechanisms. Participants were 450 men and women treated in the multisite Marijuana Treatment Project who were randomly assigned to motivational enhancement therapy plus cognitive-behavioral (MET-CB) treatment, motivational enhancement therapy (MET), or a delayed treatment control group. Marijuana use and coping skills were measured at baseline and at follow-ups through 15 months. Results showed that marijuana outcomes were predicted by treatment type and by coping skills use, but that the coping-skills-oriented MET-CB treatment did not result in greater use of coping skills than did the MET treatment. The results suggest that mechanisms of coping skills treatment may need to be reconceptualized.

0 Followers
 · 
65 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: This study aimed to test whether self-efficacy, interpersonal problems and psychological distress are significantly associated with substance use and if the factors associated with substance use are the same factors that are subject to change in treatment for patients with substance use disorders (SUDs). Methods: The sample consisted of 346 respondents, sampled from 16 treatment facilities for SUD treatment in Norway. Results and conclusions: Self-efficacy, interpersonal problems (sum-score and subscales) and psychological distress (sum-scale and subscales) were significantly associated with substance use. Clinical implications: The results suggest a gap between factors associated with substance use problems and factors that are subject to change in treatment.
    Journal of Substance Use 10/2013; DOI:10.3109/14659891.2012.685122 · 0.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There are few valid clinical assessment instruments for cannabis. Self-efficacy, or the ability of users to resist temptation, is a central feature of social cognitive theory. This study outlines the development and validation of the Cannabis Refusal Self-Efficacy Questionnaire (CRSEQ), which measures the situational confidence to refuse cannabis. One thousand two hundred and forty-six patients referred for cannabis assessment completed the CRSEQ including measures of cannabis consumption and dependence severity (Severity of Dependence Scale-Cannabis, SDS-C). The CRSEQ was subject to independent exploratory (n=621, mean age 26.88, 78.6% male) and confirmatory (n=625, mean age 27.51, 76.8% male) factor analysis. Three factors: Emotional Relief, Opportunistic and Social Facilitation were identified. They provided a good statistical and conceptual fit for the data. Emotional Relief cannabis refusal self-efficacy was identified as most predictive of cannabis dependence, after controlling for cannabis consumption. The CRSEQ is recommended as a psychometrically sound and clinically useful measure for cannabis misuse treatment planning and assessment.
    Drug and alcohol dependence 03/2012; 125(3):244-51. DOI:10.1016/j.drugalcdep.2012.02.018 · 3.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the efficacy, 3- and 6-month follow-up effects of a psychological treatment for older adolescents and adults with DSM-IV cannabis use disorders. The program was tailored to the needs of this patient population. A randomized controlled clinical trial of 122 patients aged 16 to 44 years with DSM-IV cannabis dependence as the main substance use diagnosis was conducted. Patients were randomly assigned to either Active Treatment (AT, n = 90) or a Delayed Treatment Control group (DTC, n = 32). Treatment consisted of 10 sessions of therapy, detailed in a strictly enforced manual. Assessments were conducted at baseline, during each therapy session, at post treatment and at follow-up assessments at 3 and 6 months. The treatment retention rate was 88%. Abstinence was achieved in 49% of AT patients and in 13% of those in DTC (p < 0.001; intend-to-treat (ITT) analysis). Further, AT patients improved significantly (p < = 0.001) in the frequency of cannabis use per week, addiction severity, number of disability days, and overall level of psychopathology. Program effects were maintained over a 3-month- (abstinence rate: 51%) and 6-month follow-up (45%) period. The treatment program is effective in obtaining abstinence as well as reducing cannabis use and improves the associated social and mental health burden.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 08/2011; 22(4):267-80. DOI:10.1016/j.euroneuro.2011.07.014 · 5.40 Impact Factor